Moreover, unlike ER+ or HER2+ breast cancer, for which there are targeted therapies, including anti-estrogen and monocolonal antibody therapies, there are no targeted therapies for TNBC [12, 18]. This evidence concerns the gene ESR1 and breast carcinoma.